Publication at First Faculty of Medicine |
2020
Abstract
Fusion translocations of NTRK genes rarely occur in a wide range of solid and hematological malignancies. The inhibitors of TRK receptors with kinase activity, larotrectinib and entrectinib, are a highly effective treatment option for patients with solid tumours with NTRK fusion translocation.
Entrectinib is available through a specific treatment program, larotrectinib has been registered and available upon individual reimbursement. For clinical practice in tumours with a low incidence of NTRK gene fusions, we recommend two-step testing using immunohistochemistry followed by verification using next-generation sequencing in case of a positive result.